OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
November 02, 2021
ADC development is on a positive trajectory from a deeper understanding of therapeutic mechanisms and technological advances.
November 01, 2021
A coating technology for a staked needle prefillable syringe reduces the potential risks associated with silicone oil as a lubricant.
June 20, 2019
The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.
April 01, 2019
Drug makers continue to explore innovative ways to develop antibody-drug conjugates based on their unique potential to neutralize cancer cells.
March 01, 2019
Both empty and filled syringes must pass a range of tests to meet quality standards for biopharmaceutical drugs.
November 01, 2017
Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.
September 28, 2017
Nemera is now authorized to handle, assemble, sterilize, and store pharmaceutical drugs and medicinal products for autoinjector combination products at its facility in Neuenburg, Germany.
May 30, 2017
BioVectra will open its new microbial fermentation and complex chemistry site, including the capability to handle high-potency APIs, by the end of 2017.
May 01, 2017
Recent legislation and PDUFA initiatives aim to streamline oversight and testing requirements.
April 01, 2017
OrlaSURF technology can be used for the development of target-binding assays to monitor the binding of an ADC to its antigen.